Process Chromatography: Five Decades of Innovation - - BioPharm International

ADVERTISEMENT

Process Chromatography: Five Decades of Innovation


BioPharm International
Volume 20, Issue 10

25. Janson JC, Hedman P. Large-scale chromatography of proteins. Adv Biochem Eng. 1982;25:43–99.

26. Low D. Scale-up of protein chromatographic separations. In Hancock WS (Ed). High performance liquid chromatography in biotechnology. New York: J Wiley & Sons; 1990. pp. 117–169.

27. Jungbauer A. Chromatographic media for bioseparation. J Chrom A, 2005; 1065:3–12.

28. Bren L. The Road to the biotech Revolution; Highlights of 100 years of biologics regulation. FDA Consumer Magazine, Centennial Edition, 2006; Jan–Feb.

29. Builder SE, Garnick RL, Hodgdon JC, Ogez JR. Proteins and peptides as drugs: Sources and methods of purification. In Rehm HJ and Reed G (Eds) Biotechnology, Vol 3; Bioprocessing (Stephanopoulos, G, (Ed) Weinheim, Germany: VCH. 1989, pp. 58–73.

30. Root MA, Chance RE, Galloway, JA. Immunogenicity of insulin. Diabetes, 1972;21(2):657–660.

31. Walsh G. Therapeutic insulins and their large-scale manufacture. Appl Microbiol Biotechnol, 2005;67:151–159.

32. Novo Nordisk History, pp 8–9, http://www.novo.dk/, accessed Nov 2006.

33. Lasagna L. The biological revolution: Commercialization of the molecule. Research Mgmt Rev. 1987;1:5–13.

34. Barinaga M. Asilomar revisited: Lessons for today? Science 2000;287:1584–1585.

35. US Food and Drug Administration. Guidance for industry. Research involving recombinant DNA molecules. Rockville, MD;1976.

36. Gosse ME, Manocchia M. The first biopharmaceuticals approved in the United States: 1980–1994. Drug Info J, 1996;30:991–1001.

37. Approved Biotechnology Drugs, http://www.bio.org/ (accessed Nov 2006).

38. Reichert JM, Paquette C. Therapeutic recombinant proteins: Trends in US approvals 1982–2002. Curr Op Mol Therapeutics. 2003;5(2):139–147.

39. Walsh G. Pharmaceutical biotechnology products approved within the European Union. Eur J Pharm Biopharm. 2003;55:3–10.

40. Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 2006; 24(6):274–80.

41. Pfund NE. The wheat from the chaff: The separations industry comes of age. Hambrecht & Quist, 1987.

42. Ehrenheim P. GE Healthcare presentation at bioLOGIC Asia, Mumbai, India, 2006;Nov 28–29.

43. Sofer GK, Nyström LE. Process chromatography. A practical guide. London: Academic Press; 1989.

44. Sofer GK, Nyström LE. Process chromatography. A guide to validation. London: Academic press; 1991.

45. Feldman F. Production of proteins for replacement therapy: plasma or recombinant? IBC Conference: Biological safety and Production, Boston, 1999.

46. Jungbauer A, Boschetti E. Manufacture of recombinant proteins with safe and validated chromatographic sorbents. J Chrom B. 1994;662:143–179.

47. Chase HA. Purification of proteins by adsorption chromatography in expanded beds. Trends Biotechnol. 1994;12(8):296–303.

48. Noel R. EBA for industrial scale protein isolation. Recovery of biological products XII. Arizona, 2006;Apr 2–7.

49. Fahrner RL, Knudsen HL, Basey CD, Galan W, Feuerheim D, Vanderlaan M, Blank GS. Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol Genet Eng Rev. 2001;18:301–327.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines
Source: BioPharm International,
Click here